Quality of life measurement: A suitable method for benefit-risk assessment?;Messung der Lebensqualität als Methode der Nutzen-Schaden- Abwägung?

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 105, Issue 3, 2011, Pages 157-162

  Kohlmann, Thomas ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

benefit risk assessment; modelling (As supplied by publisher); quality of life; quality adjusted life years; utility

Indexed keywords

EID: 79955552256     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2011.03.008     Document Type: Article

References (13)

1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden. Entwurf für Version 4.0. Köln, 2011 [https://www.iqwig.de/download/IQWiG-Entwurf-Methoden-Version-4-0.pdf; 20.03.2011]
2. F. Mussen, S. Salek, and S. Walker Benefit-risk appraisal of medicines: A systematic approach to decision-making 2009 Wiley Chichester
3. European Medicines Agency. Benefit-risk methodology project. Work package 2 report: Application of current tools and processes for regulatory benefit-risk assessment - EMA/549682/2010. London, 2010.
4. I. McDowell Measuring health. A guide to rating scales and questionnaires 2006 Oxford University Press Oxford
5. P. Fayers, and R. Hays Assessing quality of life in clinical trials 2005 Oxford University Press Oxford
6. S.J. Walters Quality of life outcomes in clinical trials and health-care evaluation 2009 Wiley Chichester
7. J. Brazier, J. Ratcliff, J.A. Salomon, and A. Tsuchia Measuring and valuing health benefits for economic evaluation 2007 Oxford University Press Oxford
8. A. Goldhirsch, R.D. Gelber, R.J. Simes, P. Glasziou, and A.S. Coates Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis J Clin Oncol 7 1989 36 44 (Pubitemid 19089079)
9. J. Bernhard, D. Zahrieh, A.S. Coates, R.D. Gelber, M. Castiglione-Gertsch, and E. Murray Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer Br J Cancer 91 2004 1893 1901 (Pubitemid 40065517)
10. J.P. Thompson, K. Noyes, E.R. Dorsey, S.R. Schwid, and R.G. Holloway Quantitative risk-benefit analysis of natalizumab Neurology 71 2008 357 364
11. European Medicines Agency. Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorization applications of medicinal products for human use - EMEA/CHMP/15404/2007. London, 2008.
12. L.P. Garrison, A. Towse, and B.W. Bresnahan Assessing a structured, quantitative health outcomes apporach to drug risk-benefir analysis Health Affairs 26 2007 684 695
13. S. Garattini Evaluation of benefit-risk Pharmacoeconomics 28 2010 981 986